Equities analysts predict that Stryker Co. (NYSE:SYK) will report $3.19 billion in sales for the current fiscal quarter, Zacks reports. Ten analysts have provided estimates for Stryker’s earnings, with estimates ranging from $3.15 billion to $3.22 billion. Stryker reported sales of $2.96 billion in the same quarter last year, which would suggest a positive year-over-year growth rate of 7.8%. The firm is expected to announce its next quarterly earnings results on Tuesday, April 24th.
According to Zacks, analysts expect that Stryker will report full-year sales of $3.19 billion for the current fiscal year, with estimates ranging from $13.32 billion to $13.67 billion. For the next year, analysts anticipate that the company will post sales of $14.40 billion per share, with estimates ranging from $14.22 billion to $14.55 billion. Zacks’ sales averages are an average based on a survey of research analysts that that provide coverage for Stryker.
Stryker (NYSE:SYK) last released its quarterly earnings data on Tuesday, January 30th. The medical technology company reported $1.96 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.95 by $0.01. Stryker had a return on equity of 24.56% and a net margin of 8.20%. The firm had revenue of $3.47 billion during the quarter, compared to analyst estimates of $3.42 billion. During the same period in the prior year, the company posted $1.78 earnings per share. The business’s revenue for the quarter was up 9.9% compared to the same quarter last year.
Several research firms recently issued reports on SYK. Robert W. Baird upgraded Stryker from a “neutral” rating to an “outperform” rating and boosted their price target for the company from $161.00 to $173.00 in a research note on Thursday, November 16th. JPMorgan Chase & Co. raised Stryker from a “neutral” rating to an “overweight” rating in a report on Tuesday, January 2nd. Needham & Company LLC reaffirmed a “hold” rating on shares of Stryker in a report on Friday, November 3rd. ValuEngine raised Stryker from a “hold” rating to a “buy” rating in a report on Tuesday, November 14th. Finally, Wells Fargo & Co reissued an “outperform” rating and set a $174.00 price objective (up previously from $166.00) on shares of Stryker in a research note on Tuesday, January 2nd. They noted that the move was a valuation call. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and fourteen have issued a buy rating to the company. Stryker presently has a consensus rating of “Hold” and an average target price of $162.50.
In other Stryker news, insider Lonny J. Carpenter sold 5,000 shares of the firm’s stock in a transaction dated Friday, February 2nd. The stock was sold at an average price of $163.76, for a total transaction of $818,800.00. Following the sale, the insider now owns 94,253 shares in the company, valued at $15,434,871.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, VP William E. Berry, Jr. sold 1,306 shares of the firm’s stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $164.42, for a total value of $214,732.52. The disclosure for this sale can be found here. Insiders have sold 16,840 shares of company stock worth $2,749,989 in the last 90 days. Company insiders own 7.40% of the company’s stock.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in SYK. Chemical Bank boosted its position in shares of Stryker by 24.1% in the 4th quarter. Chemical Bank now owns 12,936 shares of the medical technology company’s stock worth $2,003,000 after purchasing an additional 2,515 shares in the last quarter. Green Square Capital LLC boosted its position in shares of Stryker by 148.5% in the 4th quarter. Green Square Capital LLC now owns 5,606 shares of the medical technology company’s stock worth $871,000 after purchasing an additional 3,350 shares in the last quarter. Rehmann Capital Advisory Group boosted its position in shares of Stryker by 7.8% in the 4th quarter. Rehmann Capital Advisory Group now owns 5,306 shares of the medical technology company’s stock worth $822,000 after purchasing an additional 385 shares in the last quarter. Colonial Trust Advisors boosted its position in shares of Stryker by 40.9% in the 4th quarter. Colonial Trust Advisors now owns 33,883 shares of the medical technology company’s stock worth $5,246,000 after purchasing an additional 9,836 shares in the last quarter. Finally, Xact Kapitalforvaltning AB boosted its position in shares of Stryker by 7.3% in the 4th quarter. Xact Kapitalforvaltning AB now owns 57,539 shares of the medical technology company’s stock worth $8,909,000 after purchasing an additional 3,912 shares in the last quarter. Institutional investors and hedge funds own 74.49% of the company’s stock.
Shares of Stryker (NYSE:SYK) traded up $2.74 during trading on Thursday, reaching $161.70. The company had a trading volume of 983,059 shares, compared to its average volume of 1,533,090. Stryker has a 1-year low of $127.19 and a 1-year high of $170.00. The firm has a market cap of $60,579.61, a price-to-earnings ratio of 60.34, a PEG ratio of 2.32 and a beta of 0.70. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.59 and a current ratio of 2.29.
The company also recently declared a quarterly dividend, which will be paid on Monday, April 30th. Shareholders of record on Thursday, March 29th will be given a dividend of $0.47 per share. The ex-dividend date of this dividend is Wednesday, March 28th. This represents a $1.88 dividend on an annualized basis and a yield of 1.16%. Stryker’s payout ratio is 70.15%.
WARNING: This piece of content was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of US and international copyright law. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/02/25/stryker-co-syk-expected-to-announce-quarterly-sales-of-3-19-billion.html.
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.
Get a free copy of the Zacks research report on Stryker (SYK)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.